Eli Lilly is leading the market for GLP-1 medications (for weight loss and diabetes). In a decade, Eli Lilly could be in the ...

I am bullish on healthcare stocks, especially pharmaceuticals, due to conservative valuations. Check out the healthcare ...

Eli Lilly could extend its lead in its core therapeutic area with the launch of two new products next year. The company also ...

In today’s Pharmaceutical Executive Daily, Eli Lilly reports positive topline Phase III results for retatrutide, the FDA expands Amgen’s Uplizna label into generalized myasthenia gravis subtypes, and ...

And that's why Amazon is a top tech stock to buy and hold for 2026 and beyond.

Eli Lilly (LLY) reached $1 at the closing of the latest trading day, reflecting a +1.8% change compared to its last close.

Eli Lilly (LLY) and Company announced updated results from the Phase 3 EMBER-3 study of Inluriyo, an oral estrogen receptor antagonist, in ...

The Harbor Health Care ETF MEDI is now three years old and has performed so well that it has been rated five stars (the highest rating) within Morningstar's U.S. Fund Health category. The ...

Eli Lilly and Co. announced December 9 that it would build a new $6 billion factory in Huntsville, Alabama for production of ...

Target has expanded its protein and supplement sections as GLP-1 drugs like Ozempic reshape shopping habits, driving demand ...

Additionally, NDC-011, a novel drug combination developed through DR.NOAH's AI-based drug discovery platform, received Orphan Drug Designation (ODD) from the U.S. FDA in 2023 and IND approval for a ...

The rise of weight loss drugs such as Ozempic and Wegovy has changed the way Americans eat and shop, along with how major ...